President Donald Trump says doctors have told him that he could've become very ill with COVID-19 and credits an experimental antibody drug for helping him recover.
Trump told Rush Limbaugh in his call-in radio show on Friday that he was not in great shape and might not have recovered at all.
But the president says one day later, he was fine. Health experts say there is no way for the president or his doctors to know whether the drug was effective.
Trump says he is trying to get federal health officials to quickly approve an emergency use authorization from Regeneron Pharmaceuticals, which provides the antibody drug.
He adds it just wiped out the virus, which he says has killed five friends.
Health experts say it's not a cure, but experimental antibody drugs like those are among the most promising therapies being tested.
They aim to help the immune system fight the coronavirus. However, they are still in the testing phase and their safety and effectiveness are not yet known.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app